Provided by Tiger Trade Technology Pte. Ltd.

Compass Therapeutics, Inc.

5.49
+0.16003.00%
Post-market: 5.44-0.0500-0.91%19:11 EDT
Volume:1.37M
Turnover:7.49M
Market Cap:988.68M
PE:-13.02
High:5.56
Open:5.42
Low:5.39
Close:5.33
52wk High:6.88
52wk Low:1.33
Shares:180.09M
Float Shares:119.00M
Volume Ratio:0.54
T/O Rate:1.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4216
EPS(LYR):-0.4216
ROE:-41.29%
ROA:-25.29%
PB:5.02
PE(LYR):-13.02

Loading ...

Oct 08, 2021

Major Issues Report

8-K - Current report
Aug 16, 2021

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 05, 2021

Major Issues Report

8-K/A [Amend] - Current report
Jul 16, 2021

Correspondence

CORRESP [Cover] - Correspondence
Jul 14, 2021

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
Jun 30, 2021

Major Issues Report

8-K - Current report
Jun 04, 2021

Major Issues Report

8-K - Current report
May 13, 2021

Major Issues Report

8-K - Current report
Apr 30, 2021

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Apr 19, 2021

Major Issues Report

8-K - Current report
Mar 05, 2021

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Jan 14, 2021

Employee Stock Ownership

S-8 - Securities to be offered to employees in employee benefit plans
Dec 17, 2020

Major Issues Report

8-K - Current report
Nov 09, 2020

[Amend]Public Prospectus

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933
Nov 09, 2020

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Oct 19, 2020

Public Prospectus

S-1 - General form for registration of securities under the Securities Act of 1933
Sep 23, 2020

Correspondence

CORRESP [Cover] - Correspondence
Sep 18, 2020

[Amend]Public Prospectus

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933
Sep 15, 2020

Major Issues Report

8-K - Current report
Aug 13, 2020

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]